84216
document
Treatment with coumarin to prevent or delay recurrence of malignant melanoma . Both coumarin ( 1,2-benzopyrone ) and warfarin ( 4-hydroxycoumarin ) have been shown to prevent the recurrence of malignant melanoma . Their action is macrophage-dependent and the dosage is critical . In 1984 a multicentre , prospective , randomised , double-blind trial of coumarin , given as a daily 50-mg dose for 2 years after surgery in patients with high-risk melanoma , was started . the patients had lesions greater than 1.70 mm thick and TNM stage IB or stage II disease . To date there are 4 recurrences in the coumarin-treated group of 13 patients , and 10 recurrences in the placebo-treated group of 14 patients ( P < 0.01 ) . There were no toxic effects .
84217
Intervention_Pharmacological
coumarin
84218
Intervention_Pharmacological
coumarin
84219
Intervention_Pharmacological
warfarin
84220
Intervention_Pharmacological
coumarin
84221
Outcome_Physical
recurrences
84222
Outcome_Physical
recurrences
84223
Outcome_Adverse-effects
toxic effects
84224
Participant_Condition
malignant melanoma
84225
Participant_Condition
high-risk melanoma
84226
Participant_Condition
lesions greater than 1.70 mm thick and TNM stage IB or stage II disease